The MIR137 VNTR rs58335419 Is Associated With Cognitive Impairment in Schizophrenia and Altered Cortical Morphology

Ebrahim Mahmoudi1–3,7, Joshua R. Atkins1–3,7, Yann Quidé4,5,7, William R. Reay1–3, Heath M. Cairns1–3, Chantel Fitzsimmons1–3, Vaughan J. Carr4–6, Melissa J. Green4,5, and Murray J. Cairns*,1–3

1School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia; 2Centre for Brain and Mental Health Research, University of Newcastle, Callaghan, New South Wales, Australia; 3Hunter Medical Research Institute, New South Wales, New Lambton, Australia; 4School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; 5Neuroscience Research Australia, Randwick, New South Wales, Australia; 6Department of Psychiatry, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia; 7These authors contributed equally to the article.

*To whom correspondence should be addressed; tel: +61 (02) 4921 8670, fax: +61 (02) 4921 7903, e-mail: Murray.Cairns@newcastle.edu.au

Genome-wide association studies (GWAS) of schizophrenia have strongly implicated a risk locus in close proximity to the gene for miR-137. While there are candidate single-nucleotide polymorphisms (SNPs) with functional implications for the microRNA’s expression encompassed by the common haplotype tagged by rs1625579, there are likely to be others, such as the variable number tandem repeat (VNTR) variant rs58335419, that have no proxy on the SNP genotyping platforms used in GWAS to date. Using whole-genome sequencing data from schizophrenia patients (n = 299) and healthy controls (n = 131), we observed that the MIR137 4-repeats VNTR (VNTR4) variant was enriched in a cognitive deficit subtype of schizophrenia and associated with altered brain morphology, including thicker left inferior temporal gyrus and deeper right postcentral sulcus. These findings suggest that the MIR137 VNTR may impact neuroanatomical development that may, in turn, influence the expression of more severe cognitive symptoms in patients with schizophrenia.

Key words: MIR137 VNTR/schizophrenia/genome sequencing/neuroanatomy/cognitive deficit

Introduction

Schizophrenia is a chronic psychiatric disorder characterized by a combination of positive, negative, and cognitive symptoms. These typically emerge during late adolescence or early adulthood and are attributed to neurodevelopmental changes that alter neural connectivity and transmission.1 Schizophrenia has a very significant genetic component with heritability estimated to be around 80%2 and a lifetime risk of 0.3%–0.7%.1 Large case-control genome-wide association studies (GWAS) have made significant progress in revealing the common variation broadly distributed across the genome (with over 150 significant hits) in association with schizophrenia.3–5 While this has implicated many genes and biological pathways, the functional variants and associated genes are often obscured by the genomic complexity. There is also an unknown heritable contribution from common structural variation, including genomic insertions and deletions (INDELs) and minisatellites, such as variable number tandem repeats (VNTR) that are not captured by the major genome-wide single-nucleotide polymorphism (SNP) genotyping platforms. In some cases, these may correspond to known association regions for common SNPs and even be causal variants in linkage disequilibrium (LD) with proxy SNPs used to map the loci, as is the case for the ASMT3 VNTR.6 In other circumstances, they may not be in LD with any SNP represented in the large GWAS and may instead be an independent and unquantified component of missing heritability.

One candidate for this circumstance is the MIR137 VNTR. This 15-nucleotide repeat variant (rs58335419) is in close proximity to the miR-137 precursor sequence, including the wild-type variant (VNTRw) with 3 repeats, and 2 relatively common minor alleles with 4 repeats (VNTR4) and 5 repeats (VNTR5). While these variants do not appear to be in LD with the established genome-wide-associated SNPs,7,8 their close proximity to pre-miR-137
The VNTR has been shown to alter the expression of miR-137 at this locus, its proximity to other genes, including *DPYD*, which has also been implicated in neurological disorders, suggests that there is some uncertainty about the fine mapping that remains to be resolved.

Given that the *MIR137* VNTR has been shown to alter the expression of miR-137 and that these effects appear to be independent of the genome-wide-associated SNPs, we hypothesized that this variant may have phenotypic implications for brain development and cognitive function in schizophrenia. In support of this, we observed that the VNTR4 *MIR137* variant was significantly enriched in individuals with a cognitive deficit (CD) subtype of schizophrenia compared to healthy controls (HC). In a subset with brain imaging data, we also show that the VNTR4 is associated with significantly thicker gray matter in the left inferior temporal gyrus and deeper right postcentral sulci compared to individuals with the wild-type variant.

**Methods**

**Participants**

Data from participants meeting International Classification of Disease (ICD)-10 criteria for schizophrenia or schizoaffective disorder (*n* = 299) and HC (*n* = 131) were obtained from the Australian Schizophrenia Research Bank (ASRB), an established register of clinical, cognitive, neuroimaging, and genetic data collected by scientific collaborators across 5 Australian states and territories. Diagnoses were confirmed using the OPCRIT algorithm applied to interviewer ratings on the Diagnostic Interview for Psychosis (DIP). All participants were fluent English speakers and had no history of an organic brain disorder, brain injury accompanied by greater than 24 h of amnesia, mental retardation defined as an IQ <70, movement disorder, current substance dependence, or electroconvulsive therapy in the preceding 6 months. For this study, all participants were of European ancestry. The healthy participants additionally had no personal or family history of psychotic disorder in their first-degree biological relatives. The majority of the cases were using typical or atypical antipsychotics, mood stabilizers, and/or antidepressants; however, no dosage-equivalent information was collected by the ASRB. Sociodemographic and clinical characteristics, as well as VNTR frequencies of the cognitive subgroups are summarized in table 1.

**Clinical Assessments**

Ratings for positive symptoms were indexed using present state and lifetime ratings of hallucination (items 49–53) and delusion items (items 58–64) from the DIP and negative symptoms were indexed using the Scale for...
Table 1. Genetic, sociodemographic, clinical, and cognitive characteristics of study participants

| VNTR4 (n) | HC (n = 131) | CS (n = 150) | CD (n = 149) | Statistics | Direction |
|-----------|-------------|-------------|-------------|------------|-----------|
| Age, mean (SD) | 39.08 (13.32) | 40.10 (11.19) | 39.08 (9.78) | F(2,281.41) = 0.414, P = .661 | — |
| Sex, n (M/F) | 68/68 | 96/55 | 110/46 | X^2(2) = 13.246, P = .001 | — |
| Years of education (SD) | 15.07 (3.16) | 13.91 (2.71) | 12.23 (2.57) | F(2,284.18) = 37.402, P < .001 | HC > CS***, HC > CD***, CS > CD*** |
| Handedness, n (L/R) | 19/117 | 12/139 | 15/141 | F(2,276.92) = 73.859, P < .001 | HC > CD***, CS > CD*** |
| WASI, mean (SD) | 114.23 (12.79) | 112.15 (11.43) | 91.22 (11.59) | F(2,439) = 171.576, P < .001 | HC > CD***, CS > CD*** |

Positive Symptoms Scores (DIP items)

| Lifetime, mean (SD) | 10.93 (4.30) | 9.02 (3.97) | 2.943, P = .230 | — |
| Present state, mean (SD) | 2.70 (3.83) | 3.40 (3.57) | 1.474, P = .142 | — |

Negative Symptoms Scores (SANS, mean SD)

| Illness duration, mean (SD) | 19.70 (16.63) | 33.98 (20.03) | 6.666, P < .001 | CS > CD |
| Typical antipsychotics, n (%) | 7 | 17 | 3.295, P = .114 | — |
| Atypical antipsychotics, n (%) | 127 | 128 | 1.004, P = 1.000 | — |
| Antidepressants, n (%) | 47 | 44 | 0.170, P = .738 | — |
| Mood stabilizers, n (%) | 24 | 19 | 0.913, P = .440 | — |

**Note:** HC, healthy controls; CS, cognitively spared schizophrenia cases; CD, schizophrenia cases with cognitive deficits; VNTR4, 4-repeats variable number tandem repeat; M/F, males/females; L/R, left/right; DIP, Diagnostic Interview for Psychosis; SANS, Scale for the Assessment of Negative Symptoms; WTAR, Wechsler Test of Adult Reading; WASI, Wechsler Abbreviated Scale of Intelligence.

*P < .05; **P < .01; ***P < .001

Assessment of Negative Symptoms. Premorbid and current intelligence levels were assessed with the Wechsler Test of Adult Reading and the Wechsler Abbreviated Scale of Intelligence, respectively, and handedness was assessed with the Edinburgh Handedness Inventory.

Cognitive Clustering

Grade of Membership analysis was performed with the DSIGoM software (beta version 1.01, Decision Systems, 1999; [http://www.dsisoft.com](http://www.dsisoft.com)) using cognitive performance data collected from schizophrenia patients only, as detailed in our previous work (see supplementary material). Use of this method applied previously to ASRB participants partitioned the clinical cases into groups presenting severe cognitive deficits (CD; n = 149) relative to those with relatively spared cognitive function (CS; n = 150) as described in Green et al. Sociodemographic and clinical characteristics, as well as VNTR frequencies, of the cognitive subgroups are summarized in table 1.

DNA Sequencing

Whole-genome sequencing was performed on the ASRB cohort for 299 schizophrenia cases (comprising 149 CD and 150 CS cases) and 131 HC, at the Garvan Institute of Medical Research: Kinghorn Centre for Clinical Genomics (Darlinghurst, New South Wales, Australia). A 20-ml blood sample collected at the time of the clinical interview was used to extract DNA. High-integrity genomic DNA from peripheral blood mononuclear cells (1 μg) was sequenced using the Illumina HiSeq X platform as described with 2 × 150 base pair paired-end reads. The sequencing coverage was a minimum mean yield of 30×. The Phred quality score of 75% of bases was greater than 30.

Variant Calling

Raw reads (FASTQ) were aligned to the hg19 reference using Bowtie2 ([http://bowtie-bio.sourceforge.net/bowtie2/index.shtml](http://bowtie-bio.sourceforge.net/bowtie2/index.shtml)) before compression, sorting, and indexing with Samtools. Picard tools ([http://broadinstitute.github.io/picard/](http://broadinstitute.github.io/picard/)) were then used to mark and remove PCR duplicates. Quality score recalibration and indel realignment were then carried out using the GATK3 BaseRecalibrator and IndelRealigner, respectively. Variants within the region defined by Ripke et al. were called using the HaplotypeCaller, followed by joint genotyping with GenotypeGVCFs. Variant calling was conducted using at least 20 reads per sample covering the VNTR site with a minimum of 4 reads per allele. We used best practices as per GATK guidelines. VCF files were converted into a matrix with zygosity for each allele. Principal component analysis was performed to adjust for the population stratification and was used to remove non-European samples. VNTR4 carriers included 48 cases
(CD = 27; CS = 21) and 12 controls and noncarriers included 251 cases (CD = 122; CS = 129) and 119 controls.

Magnetic Resonance Imaging Acquisition and Preprocessing

Participants with available genetic, cognitive, and magnetic resonance imaging (MRI) data included 174 clinical participants with a diagnosis of schizophrenia (n = 155) or schizoaffective disorder (n = 19; together referred to as the schizophrenia group) and 97 HC. Among the schizophrenia cases, 106 were classified as CS, and 68 classified as CD (see table 2). Details of MRI scans and processing are provided in the supplementary material.

Statistical Analysis

VNTR enrichment among cognitive subtypes of schizophrenia. To test for the enrichment of VNTR4 among cognitive subtypes of schizophrenia as well as in the diagnosis groups, a binomial logistic regression model was constructed and adjusted for sex, SNP rs1625579, and the first 3 principal components in 299 participants with schizophrenia (149 CD and 150 CS) compared to 131 HC. Wald test was used to calculate the P values for both models; analysis was performed using Statsmodels libraries from Python.38 The significance threshold was set at P < .05.

MIR137 VNTR Polymorphism in Association With Altered Brain Morphology. Descriptive statistics for the sub-sample of participants included in the neuroimaging analyses were performed using SPSS 24 (IBM, SPSS Inc.), with significance set at P < .05 (2 tailed). Indices of effect size (partial eta-squared, \( \eta^2 \), and Cohen’s d) are reported. For neuroimaging analyses (CAT12), measures of total gray matter volume (GMV), white matter volume (WMV), and cerebro-spinal fluid (CSF) volumes were extracted. To determine the main effects of the cognitive subgroups, of the presence of the VNTR4, and their potential interaction on these tissue-specific indices, a 3 (groups: HC vs CS vs CD) by 2 (VNTR4: present vs absent) MANCOVA was used (initial threshold P < .05). Where appropriate, this was followed by (within-group) univariate ANCOVAs with Bonferroni correction applied for the number of dependent variables (ie, GMV, WMV, and CSF, P < .017). Age, sex, SNP rs1625579 genotype (GG/GT/TT; to control its potential independent effect on brain morphology), and scanning location were entered as covariates for all imaging analysis. Total intracranial volume was also included as a covariate for whole-brain tissue-specific masks and voxel-based morphometry (VBM) but not for cortical thickness, gyrification, sulcal depth, and analyses. A similar 2 (groups: HC vs SZ) by 2 (VNTR4: present vs absent) MANCOVA was conducted for reference, with results presented in supplementary material. A whole-brain 3 (HC vs CS vs CD) by 2 (VNTR4: present vs absent) ANCOVA was conducted on whole-brain volumes (VBM). To account for and exclude voxels related to potential artifacts or misclassified at the gray/white matter border, we applied an internal gray matter threshold of 0.2 for VBM analyses. Similar to VBM analyses, indices of cortical thickness, gyrification, and sulcal depth were used as dependent variables in a series of whole-brain ANCOVAs [P(FWEc) < .05]. For each index of brain morphology (whole-brain volume, cortical thickness, sulcal depth, and gyrification) the statistical inference was made separately using an initial voxel-level threshold of P < .001 uncorrected, to which a cluster-level family-wise error (FWE) correction was applied [P(FWEc) < .05]. Regions showing significant GMV differences were identified using the Neuromorphometrics atlas in DARTEL space, as implemented in CAT12 for VBM analyses, and using the Desikan–Killiany atlas39 for surface-based analyses. For reference, a series of similar 2 (groups: HC vs SZ) by 2 (VNTR4: present vs absent) ANCOVAs were performed for each index of brain morphology with results presented in supplementary material.

Results

The VNTR4 is Associated With CD Subtypes of Schizophrenia

To investigate the potential impact of MIR137 VNTR length, we used DNA sequencing data obtained for individuals in the ASRB as this variant cannot be imputed from GWAS SNP data. Three alleles of the VNTR were observed, including VNTRa, VNTRb, and VNTRc, with a frequency of 0.91, 0.085, and 0.001, respectively. Participants carrying the rare VNTRc variant were excluded from these analyses as we were underpowered to determine its association. The VNTR4 genotype was observed to be enriched within the CD subtype relative to the control group (P = .03, odds ratio [OR] = 1.92, 95% CI [1.04, 3.55]; figure 1). This was confirmed by the absence of difference between the CS group and controls (P = .67, OR = 1.15, 95% CI [0.59, 2.25]), CD and CS groups (P = .05, OR = 1.69, 95% CI [0.98, 2.92]), and combined case-control comparison (P = .11, OR = 1.58, 95% CI [0.89, 2.79]; figure 1).

MIR137 VNTR Polymorphism Is Associated With Altered Cortex Morphology

Sociodemographic and clinical characteristics of the imaging cohort, a subset of the main cohort, are summarized in table 2 and in supplementary material. The 3 × 2 ANCOVA on whole-brain tissue masks showed that there were no significant main effect of group (Wilk’s lambda = 0.955, \( F_{3,254} = 1.985 \), \( P = .066, \eta^2 = 0.023 \), presence of the VNTR4 (Wilk’s lambda = 0.979, \( F_{3,254} = 1.846 \), \( P = .139, \eta^2 = 0.021 \), or
| Table 2. Sociodemographic, clinical characteristics, genotype, and allelic frequencies for the cognitive subgroups with magnetic resonance imaging scans |
|-----------------------------------|----------------|----------------|----------------|----------------|----------------|
|                                  | HC (n = 97)    | CS (n = 106)   | CD (n = 68)    | Statistics     | Direction      |
| Age, mean (SD)                   | 41.87 (13.41)  | 39.97 (11.16)  | 37.78 (8.16)   | Welch = 3.104, df = 2,175.13, P = .047, ηp² = 0.019 | ns             |
| Sex, n (M/F)                     | 47/50          | 72/34          | 46/19          | X² = 12.054, df = 2, P = .002 |                |
| Years of education (SD)          | 15.11 (2.92)   | 13.79 (2.81)   | 12.32 (2.42)   | F = 20.562, df = 2,268, P < .001, ηp² = 0.127 | HC > CS**, CD***, CS > CD** |
| Handedness, n (L/R)              | 16/81          | 9/97           | 8/60           | X² = 3.049, df = 2, P = .218 |                |
| WTAR, mean (SD)                  | 105.54 (10.82) | 106.58 (9.03)  | 92.40 (14.17)  | Welch = 27.485, df = 2,147.88, P < .001, ηp² = 0.223 |                 |
| WASI, mean (SD)                  | 115.81 (11.43) | 113.12 (9.76)  | 94.32 (11.39)  | F = 89.720, df = 2,268, P < .001, ηp² = 0.395 | HC, CS > CD*** |
| Positive Symptoms Scores (DIP items) |                |                |                |                |                |
| Lifetime, mean (SD)              | —              | 10.89 (4.31)   | 8.93 (3.84)    | t = 2.748, df = 136, P = .007, d = 0.48 | |
| Present state, mean (SD)         | —              | 2.48 (3.44)    | 3.54 (3.37)    | t = 1.803, df = 136, P = .074, d = 0.31 | |
| Negative Symptoms Scores (SANS)  | —              | 18.15 (14.81)  | 29.80 (18.38)  | t = 4.453, df = 161, P < .001, d = 0.70 | |
| Illness duration, mean (SD)      | —              | 15.92 (10.57)  | 14.38 (8.76)   | t = 1.044, df = 160.93, P = .298, d = 0.16 | |
| Typical antipsychotics, n (%)    | —              | 8 (8%)         | 4 (6%)         | X² = 0.778, df = 1, P = .418 |                |
| Atypical antipsychotics, n (%)   | —              | 87 (82%)       | 56 (82%)       | X² = 0.641, df = 1, P = .1000 |                |
| Antidepressants, n (%)           | —              | 32 (30%)       | 19 (28%)       | X² = 1.161, df = 1, P = .531 |                |
| Mood stabilizers, n (%)          | —              | 12 (11%)       | 7 (10%)        | X² = 0.08, df = 1, P = 1.000 |                |
| Scan sites, n                    |                |                |                |                  |                |
| Brisbane                         | 19             | 41             | 36             | X² = 29.707, df = 8, P < .001 | |
| Melbourne                        | 45             | 26             | 11             |                               |                |
| Newcastle                        | 10             | 7              | 4              |                               |                |
| Perth                            | 9              | 10             | 5              |                               |                |
| Sydney                           | 14             | 22             | 12             |                               |                |
| Genotypes, n (%)                 |                |                |                |                  |                |
| GG                               | 10 (10%)       | 1 (1%)         | 2 (3%)         | X² = 10.710, df = 4, P = .030 | |
| GT                               | 30 (31%)       | 33 (31%)       | 23 (34%)       |                               |                |
| TT                               | 57 (59%)       | 72 (68%)       | 43 (63%)       |                               |                |
| VNTR+, present/absent (% present) | 12/85 (14%)    | 18/88 (20%)    | 18/50 (36%)    | X² = 5.516, df = 2, P = .063 | |
| Imaging                          |                |                |                |                               |                |
| Total GMV, mm³ (SD)              | 686.82 (71.86) | 705.09 (77.86) | 682.56 (67.83) |                           |                |
| Total WMV, mm³ (SD)              | 554.48 (61.34) | 554.55 (63.91) | 544.90 (71.62) |                           |                |
| Total CSF, mm³ (SD)              | 325.25 (65.02) | 351.03 (64.98) | 349.29 (66.79) |                           |                |
| TIV, mm³ (SD)                    | 1547.55 (144.41) | 1610.68 (153.61) | 1576.75 (153.17) |                           |                |

Note: HC, healthy controls; SZ/SZA, clinical cases diagnosed with schizophrenia (SZ, n = 155) or schizoaffective disorder (SZA, n = 19); df, degrees of freedom; d, Cohen's d; M/F, males/females; L/R, left/right; DIP, Diagnostic Interview for Psychosis; SANS, Scale for the Assessment of Negative Symptoms; WTAR, Wechsler Test of Adult Reading; WASI, Wechsler Abbreviated Scale of Intelligence; GMV, gray matter volume; WMV, white matter volume; CSF, cerebro-spinal fluid; TIV, total intracranial volume. P < .05 are presented in bold typeface. *P < .05; **P < .01; ***P < .001.
their interaction (Wilk’s lambda = 0.980, $F_{6,508} = 0.841$, $P = .539$, $\eta^2 = 0.010$) on these measures. Whole-brain VBM analyses showed a main effect of cognitive subgroups on the volume of the left entorhinal gyrus (see table 3 and figure 2), with the HC group showing significantly larger volume than both the CS and CD group in this region (all post hoc $P < .001$). There were no significant effects of the presence of the VNTR$_4$ or group-by-VNTR$_4$ interaction on GMV. In addition, there were significant main effects of the presence of the VNTR$_4$ on indices of cortical thickness and sulcal depth (see table 3 and figure 3), with VNTR$_4$ carriers showing thicker left inferior/middle temporal gyrus (post hoc $P < .001$) and deeper right postcentral sulcus (post hoc $P < .001$) compared to noncarriers. There were no significant main effects of group or group-by-VNTR$_4$ interaction on these indices, and there were no significant effects of group, presence of the VNTR$_4$, or their interaction on indices of cortical gyrification.

**Discussion**

This study investigated the $MIR137$ VNTR rs58335419 heterogeneity in association with cognitive and neuroanatomical phenotypes in a relatively large cohort of schizophrenia cases and healthy individuals from the ASRB. Carriers of the VNTR$_4$ were enriched in a CD subtype of schizophrenia, identified via latent class analysis of cognitive performance across multiple neuropsychological tests. While no significant difference was observed in direct comparison of cases and controls, we suspect this may be due to the disproportionate number of cases having relatively mild cognitive impairment. This was consistent with previous studies that also reported no association between the $MIR137$ variants (including VNTR) and SZ or SZ and/or BD. Interestingly, when we further investigated the neuroanatomical features associated with the VNTR$_4$ genotype, we observed thicker left inferior/middle temporal gyrus and deeper right postcentral sulcus compared to the group with the VNTR wild type.

Our findings, therefore, suggest that the $MIR137$ variants, particularly the VNTR$_4$, have a stronger association with cognitive and neuroanatomical endophenotypes of SZ than the disease diagnosis. This is consistent with previous reports suggesting that phenotypic changes associated with the $MIR137$ risk allele are independent of psychiatric diagnoses and may be more closely aligned with cognitive endophenotypes. For example, lower performance to a Stroop task, which has been consistently reported in schizophrenia, was found in healthy VNTR$_4$ carriers compared to wild-type participants. Another study reported more cognitive deficits involving episodic memory and attentional control impairments in individuals carrying the schizophrenia GWAS-associated variant rs1625579 in a mixed cohort.
Fig. 2. Whole-brain gray matter volume changes associated with cognitive subgroups of schizophrenia cases compared to healthy controls (HC). Volume of the left entorhinal gyrus was significantly larger in HC compared to both the cognitively spared (CS) and cognitive deficits (CD) groups (post hoc \( P < .001 \)). a.u.: arbitrary units; color bar represents \( F \)-statistics; coordinates are reported in Montreal Neurologic Institute space; error bars represent 95% CI; VNTR, variable number tandem repeat.

Fig. 3. Whole-brain surface-based gray matter changes associated with the variable number tandem repeat (VNTR) genotype. Left inferior/middle temporal gyrus (left) and right postcentral sulcus (right) were significantly thicker and deeper, respectively, in 4-repeats VNTR (VNTR4) carriers compared to noncarriers (post hoc \( P < .001 \)). a.u.: arbitrary units; color bar represents \( p \)-value; error bars represent 95% CI.
of schizophrenia and bipolar disorder. The same variant was associated with the P300 electrophysiological endophenotype in schizophrenia and impaired performance in verbal episodic memory and attention. Previous work from our group demonstrated that patients carrying this variant in combination with more severe negative symptoms predicted membership of a subtype of schizophrenia cases presenting severe cognitive deficits.

In line with our findings concerning altered brain morphology among VNTR4 carriers, previous functional neuroimaging studies have implicated the inferior temporal gyrus in multiple cognitive processes, including language, visual perception, and multimodal sensory integration. The inferior temporal gyrus is also specifically associated with the recognition of objects/patterns using visual categories, which is often impaired in schizophrenia. The postcentral sulcus is at the border of the postcentral gyrus and parietal lobules; the former is somatosensory cortex whose abnormal processing contributes to deficits seen in neurological disorders, and the later play key roles in the control of action. Genetic variation in the MIR137 locus has also been associated with brain morphological and functional changes; eg, marker SNP rs1625579 was associated with small white matter density, reduced hippocampal volume, and larger lateral ventricles in schizophrenia patients compared to HC. Similar studies have also reported evidence of the association between the rs1625579 and decreased brain volume, increased brain functional activity, altered fronto-amygdala connectivity, and reduced white matter integrity.

MIR137 encodes for mir-137, a brain-enriched miRNA that has been shown to regulate several processes thought to contribute to the pathogenesis of schizophrenia, including neurodevelopment, neural maturation and transmission, adult neurogenesis, and synaptogenesis. The schizophrenia-associated MIR137 variants are thought to exert functional consequence through the alteration of miR-137 expression. For example, neurons harboring the schizophrenia-risk haplotype have decreased levels of miR-137 compared to cells carrying the alternative allele. This finding is consistent with reduced levels of miR-137 associated with the risk allele in postmortem tissue from the human dorsolateral prefrontal cortex. Expression of miR-137 was shown to be directly altered by the VNTR, with reduced levels observed to emerge from the VNTR-containing cells compared to their wild-type counterparts. MiR-137 target genes were also differentially expressed in transcriptomic analysis of the VNTR-containing cells and enriched in pathways involved in synaptogenesis, synapse organization, and synaptic transmission. More recently it was reported that the longer variants including VNTR modulate alternative splicing of the pri-miR-137, resulting in reduced expression of miR-137 in fetal and adult human brains. However, previous reports, including ours, have shown that postmortem alteration in the miR-137 expression in the cerebral cortex was not significantly different in SZ. This is probably due to the fact that the samples were not stratified by genotype and were also subject to modulation by a variety of environmental exposures. It is also possible that the miR-137 expression is more critical and variable during the early development of the nervous system and, therefore, not detected in post-mortem samples with the disorder.

This study has limitations associated with sample size that needs to be acknowledged. Future studies with larger sample size are, therefore, warranted to specifically test the association of this multiallelic variant between cognitive endophenotypes and in relation to diagnosis of the disorder. We were also underpowered to examine the effect of the rare VNTR variant, which had an allele frequency of 0.01 in our cohort. We suspect that the VNTR may also be associated with a diagnosis of schizophrenia and this signal may emerge in a much larger sequenced sample as we were also underpowered to detect an association with the GWAS risk SNP.

In summary, these findings suggest that the MIR137 VNTR4 genotype is enriched in individuals with a severe CD subtype of schizophrenia. The VNTR4 variant was also associated with altered brain morphology in the inferior temporal gyrus and postcentral sulci. We suspect that the functional significance of the VNTR4 is associated with dysregulation of miR-137, supporting the gene's role in the cognitive aspects of the disorder more generally and the mounting evidence of its significance to brain development and function. It is also plausible that this miRNA is a candidate for therapeutic manipulation in individuals with schizophrenia, particularly those that have genomic variation in its gene and/or its biosynthesis and effector pathways. The significance of this cannot be underestimated given the unmet need for drugs that target the most intractable cognitive symptoms of schizophrenia that are associated with poor functional outcomes. More broadly, our observations suggest that some common structural variants in the genome that are not currently tagged by proxy SNP content on the major genotyping platforms may account for a significant burden of the missing heritability of complex traits and warrant further attention in future efforts to capture common genetic liability of disease. In some cases, such as the VNTR rs58335419 analyzed in the current study, these variants may provide additional support to the gene targets of causal variation in undifferentiated GWAS loci.

Supplementary Material
Supplementary material is available at Schizophrenia Bulletin.
Funding
This study was supported by the NSW Health Collaborative Genomics grant program (M.C., M.G., and V.C.), a National Alliance for Research on Schizophrenia and Depression Independent Investigator Grant (M.C.), and National Health and Medical Research Council project grants (1067137, 1147644, and 1051672). Data and samples were also collected by the Australian Schizophrenia Research Bank (ASRB), supported by an Australian National Health and Medical Research Council Enabling Grant (386500), the Pratt Foundation, Ramsay Health Care, and the Viertel Charitable Foundation. The ASRB were also supported by the Schizophrenia Research Institute (Australia), utilizing infrastructure funding from NSW Health and the Macquarie Group Foundation. E.M. is supported by a University of Newcastle RHD scholarship. J.A. is supported by a University of Newcastle RHD scholarship and an Emlyn and Jennie Thomas Postgraduate Medical Research Scholarship. W.R. is supported by an Australian Postgraduate Research Award. M.C. is supported by a National Health and Medical Research Council Senior Research Fellowship (1121474).

Conflict of interest: The authors declare no conflict of interest.

References
1. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635–645.
2. Gejman PV, Sanders AR, Duan J. The role of genetics in the etiology of schizophrenia. Psychiatr Clin North Am. 2010;33(1):35–66.
3. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–427.
4. Li Z, Chen J, Yu H, et al. Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia. Nat Genet. 2017;49(11):1576–1583.
5. Pardíñas AF, Holmans P, Pocklington AJ, et al; GERAD1 Consortium; CRESTAR Consortium. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;50(3):381–389.
6. Li M, Jaffe AE, Straub RE, et al. A human-specific AS3MT isoform and BORCS7 are molecular risk factors in the 10q24.32 schizophrenia-associated locus. Nat Med. 2016;22(6):649–656.
7. Warburton A, Breen G, Rujescu D, Bubbl VI, Quinn JP. Characterization of a REST-regulated internal promoter in the schizophrenia genome-wide associated gene MIR137. Schizophr Bull. 2015;41(3):698–707.
8. Warburton A, Breen G, Bubbl VI, Quinn JP. A GWAS SNP for schizophrenia is linked to the internal MIR137 promoter and supports differential allele-specific expression. Schizophr Bull. 2016;42(4):1003–1008.
9. Bemis LT, Chen R, Amato CM, et al. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res. 2008;68(5):1362–1368.
10. Strazisar M, Cammaerts S, van der Ven K, et al. MIR137 variants identified in psychiatric patients affect synaptogenesis and neuronal transmission gene sets. Mol Psychiatry. 2015;20(4):472–481.
11. Mahmoud E, Cairns MJ. MIR-137: an important player in neural development and neoplastic transformation. Mol Psychiatry. 2017;22(1):44–55.
12. Silber J, Lim DA, Petritsch C, et al miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008;6:14.
13. Sun G, Ye P, Murai K, et al. miR-137 forms a regulatory loop with nuclear receptor TLX and LSD1 in neural stem cells. Nat Commun. 2011;2:529.
14. Collins AL, Kim Y, Bloom RJ, Kelada SN, Sethupathy P, Sullivan PF. Transcriptional targets of the schizophrenia risk gene MIR137. Transl Psychiatry. 2014;4:e404.
15. Guella I, Sequeira A, Rollins B, et al. Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. J Psychiatr Res. 2013;47(9):1215–1221.
16. Wright C, Turner JA, Calhoun VD, Perrone-Bizzozero N. Potential impact of miR-137 and its targets in schizophrenia. Front Genet. 2013;4:58.
17. Schizophrenia Psychiatric Genome-Wide Association Study Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43(10):969–976.
18. Kwon E, Wang W, Tse IH. Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TFCF4 as miR-137 targets. Mol Psychiatry. 2013;18(1):11–12.
19. Kim AH, Parker ER, Williamson V, McMichael GO, Fanous AH, Vladimirov VI. Experimental validation of candidate schizophrenia gene ZNF804A as target for hsa-miR-137. Schizophr Res. 2012;141(1):60–64.
20. Cummings E, Donohoe G, Hargreaves A, et al. Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at MIR-137. Neurosci Lett. 2013;532:33–38.
21. Mothersill O, Morris DW, Kelly S, et al. Effects of MIR137 on fronto-amygdala functional connectivity. Neuroimage. 2014;90:189–195.
22. Kuswanto CN, Sum MY, Qiu A, Sitoh YY, Liu J, Sim K. The impact of genome wide supported microRNA-137 (MIR137) risk variants on frontal and striatal white matter integrity, neurocognitive functioning, and negative symptoms in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2015;168B(5):317–326.
23. Lett TA, Chakravarty MM, Chakravarty MM, et al. The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Mol Psychiatry. 2013;18(4):443–450.
24. World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems. 10th rev. ed. New York, NY: World Health Organization; 2008.
25. Loughland C, Draganic D, McCabe K, et al. Australian Schizophrenia Research Bank: a database of comprehensive clinical, endophenotypic and genetic data for aetiological studies of schizophrenia. Aust N Z J Psychiatry. 2010;44(11):1029–1035.
26. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991;48(8):764–770.
31. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. *Neuropsychologia*. 1971;9(1):97–113.

32. Green MJ, Cairns MJ, Wu J, et al; Australian Schizophrenia Research Bank. Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. *Mol Psychiatry*. 2013;18(7):774–780.

33. Reay WR, Atkins JR, Quide Y, Carr VJ, Green MJ, Cairns MJ. Polygenic disruption of retinoid signalling in schizophrenia and a severe cognitive deficit subtype. *Mol Psychiatry*. 2020;25:719–731.

34. Li H, Handsaker B, Wyssker A, et al; 1000 Genome Project Data Processing Subgroup. The sequence alignment/map format and SAMtools. *Bioinformatics*. 2009;25(16):2078–2079.

35. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 2010;20(9):1297–1303.

36. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet.* 2011;43(5):491–498.

37. Poplin R, Ruano-Rubio V, DePristo MA, et al. (2018) ‘Scaling accurate genetic variant discovery to tens of thousands of samples’, bioRxiv, doi:10.1101/201178, July 24, 2018, preprint: not peer reviewed.

38. Seabold S, Perktold J. Statsmodels: econometric and statistical modeling with python. Paper presented at: 9th Python SciPy Conference; June 28–30, 2010; Austin, TX.

39. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage*. 2006;31(3):968–980.

40. Egawa J, Nunokawa A, Shibuya M, et al. Resequencing and association analysis of MIR137 with schizophrenia in a Japanese population. *Psychiatry Clin Neurosci.* 2013;67(4):277–279.

41. van Erp TG, Guella I, Vawter MP, et al. Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation. *Biol Psychiatry*. 2014;75(5):398–405.

42. Liu B, Zhang X, Hou B, et al. The impact of MIR137 on dorsolateral prefrontal-hippocampal functional connectivity in healthy subjects. *Neuropsychopharmacology*. 2014;39(9):2153–2160.

43. Westerhausen R, Kompu K, Hugdahl K. Impaired cognitive inhibition in schizophrenia: a meta-analysis of the Stroop interference effect. *Schizophr Res.* 2011;133(1-3):172–181.

44. Chen EY, Wong AW, Chen KY, Au JW. Stroop interference and facilitation effects in first-episode schizophrenic patients. *Schizophr Res.* 2001;48(1):29–44.

45. González-Giraldo Y, González-Reyes RE, Forero DA. A functional variant in MIR137, a candidate gene for schizophrenia, affects Stroop test performance in young adults. *Psychiatry Res.* 2016;236:202–205.

46. Decoster J, De Hert M, Viechtbauer W, et al. Genetic association study of the P300 endophenotype in schizophrenia. *Schizophr Res.* 2012;141(1):54–59.

47. Cabeza R, Nyberg L. Imaging cognition II: an empirical review of 275 PET and fMRI studies. *J Cogn Neurosci.* 2000;12(1):1–47.

48. Herath P, Kinomura S, Roland PE. Visual recognition: evidence for two distinctive mechanisms from a PET study. *Hum Brain Mapp.* 2001;12(2):110–119.

49. Mesulam MM. From sensation to cognition. *Brain*. 1998;121(Pt 6):1013–1052.

50. Butler PD, Javitt DC. Early-stage visual processing deficits in schizophrenia. *Curr Opin Psychiatry*. 2005;18(2):151–157.

51. Borich MR, Brodie SM, Gray WA, Ionta S, Boyd LA. Understanding the role of the primary somatosensory cortex: Opportunities for rehabilitation. *Neuropsychologia*. 2015;79(Pt B):246–255.

52. Sakamoto K, Crowley JJ. A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia. *Am J Med Genet B Neuropsychiatr Genet*. 2018;177(2):242–256.

53. Siegert S, Cho J, Kwon EJ, et al. The schizophrenia risk gene product miR-137 alters presynaptic plasticity. *Nat Neurosci.* 2015;18(7):1008–1016.

54. Pacheco A, Berger R, Freedman R, Law AJ. A VNTR regulates miR-137 expression through novel alternative splicing and contributes to risk for schizophrenia. *Sci Rep.* 2019;9(1):11793.

55. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ. Schizophrenia is associated with an increase in cortical microRNA biogenesis. *Mol Psychiatry*. 2010;15(12):1176–1189.

56. Beveridge NJ, Tooney PA, Carroll AP, et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. *Hum Mol Genet.* 2008;17(8):1156–1168.

57. Mellios N, Galdzicka M, Ginn E, et al. Gender-specific reduction of estrogen-sensitive small RNA, miR-30b, in subjects with schizophrenia. *Schizophr Bull.* 2012;38(3):433–443.